medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the twelfth consecutive year, Roche has been recognised as one of the most sustainable companies in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI). The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2019 employed about 98,000 people worldwide. In 2019, Roche invested CHF 11.7 billion in R&D and posted sales of CHF 61.5 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit https://www.globenewswire.com/Tracker?data=f80K8YBDFMyK0FHs3YP9myOmEafICaAMKaa1Zu9tl58ZLFptNqlVTYiMS-bdcMW3jKnVzmwwWFAUjaaCZQ2SYg== www.roche.com. All trademarks used or mentioned in this release are protected by law. References [1] Hayden F, et al. Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents. N Engl J Med 2018; 379:913-923. [2] Ison M, et al. Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial. Lancet Infect Dis. 2020;20(10):1204-1214. [3] Ikematsu H, et al. Baloxavir Marboxil for Prophylaxis against Influenza in Household Contacts. N Engl J Med. 2020; 383.309-320. [4] EMA. Tamiflu. [Internet; cited 2020 November]. Available from: https://www.globenewswire.com/Tracker?data=8bMQ-w4R4B0FCrxi1j0taSzFHK5th4hOixWpiYHeiFgP7U5R0a34jRlz7hyyztmwP2GhBYGzsftVFbp60VZLXLMUvvtF2oIvXESkOCfocX123UPzftLZ55oSuI07UgkHgQtLtVRvg1XvY0c6VaSiRxVYP8schnyrjtvqf5ONROpDMUdJFV7OxflIxWtLL7DW https://www.ema.europa.eu/en/medicines/human/EPAR/tamiflu [5] Centers for Disease Control and Prevention. Disease burden of influenza. [Internet; cited 2020 November]. Available from: https://www.globenewswire.com/Tracker?data=8bMQ-w4R4B0FCrxi1j0taSaIOH4mijXNVTdXaopdrk7cszqjaQ-d0jBUNtpvXKYLVynD32U7_i1ZQ_9auZrolsyo717uafKLl82u-XTWGRZTXUFjj4pJqy26KuJdfYUlgTSFsce4F00wZ1fL45y7F8hJs0zcDbcnf6aYnM00j6c= https://www.cdc.gov/flu/about/burden/index.html [6] World Health Organization. Public Health Research Agenda for Influenza. [Internet; cited 2020 November]. Available from: https://www.globenewswire.com/Tracker?data=8bMQ-w4R4B0FCrxi1j0taVtWDTn5b5LFMHt59DyoYgy0JL2AKVad3muCIjDaqCkrnYyNW-5cUCP_agfqO-e_hw4WYnCNJ85SgTyFGonzM4aaYmt-trjrct5qwUjPYjOSUf86380aHAitriKBvgDwh0LbEb5weN_0ayvHi4Fev9lbwVvTAPNM0OKfa6V6Kf5D0ZOgPd2p0cAq_BV_YV2JtHH-lNd3t-dMDvVPuYQ1H1YMospQ-H_fWFgNt7Z2KTiGHePPINxSL7kMrOFmvcNG_znn-UI1ofKE7bHuORAee33drpL3BkrMzAIfnUadcTwdG0UPQ0kOS8wegHUyN_2osw== https://www.who.int/influenza/resources/research/2010_04_29_global_influenza_research_agenda_version_01_en.pdf [7] World Health Organization. Global Influenza Strategy 2019-2030. [Internet; cited 2020 November]. Available from: https://www.globenewswire.com/Tracker?data=8bMQ-w4R4B0FCrxi1j0taVtWDTn5b5LFMHt59DyoYgzZVGWW2BRP_f6l3qhMnnRDqPwGnZM9HCaH48JVNUCqzcAnSMnDrse_HehmwWmY2C0p8Rr1LG1gfyzq13efr-DDgBGsz9KaqRRN7irbm0x9PJA6O5zGjlTAMWYBmWJ7xu1AGyynqNuOOWXcVIfkdrQw2UbZZRmKXh2uOLh54Xx8TGPk1kYJzav3A9f2wIDZBGaS7Ag2c6Lh_Y4wILYBipEk_F_wNI-iqyyC4Xtcncs43g== https://www.who.int/influenza/Global_Influenza_Strategy_2019_2030_Summary_English.pdf?ua=1 [8] World Health Organization. Influenza (seasonal). [Internet; cited 2020 November]. Available from: https://www.globenewswire.com/Tracker?data=8bMQ-w4R4B0FCrxi1j0taVtWDTn5b5LFMHt59DyoYgyd7K2qQx8dutnM1ngD3YJexjaVFNEnl5QumJLrYMP1P_7jaIVb3XHPD36oHFurAXZVIXZAiZPcKIuPwVbenxynuwTl2V3S6cxfpp_iQgvJVdzCC5JJaw8EFbage6rea8QC-GynSU4KglNHz6WX6gPx2M4Z5zl1Z61ntnEeTPRJLsy0G5ZuIVrAmrHhUiZ_SJ0= https://www.who.int/news-room/fact-sheets/detail/influenza-(seasonal) [9] Choi WS, et al. Severe influenza treatment guideline. Korean J Intern Med. 2014; 29.1.132-147. [10] World Health Organization. Influenza -- estimating the burden of disease. [Internet; cited 2020 November]. Available from: https://www.globenewswire.com/Tracker?data=8bMQ-w4R4B0FCrxi1j0taUS5zu5tPmBPFDOmb2HunljH71lX5CCe8ACGLPlpvzGit62w2bDwt2b0HcO8iCjJv2plIz9oXkJbOIfupylRQYhTOYNW9d9uiMC842jij5R2wrugiPAf1zc6vwHqSJdR85heuo-ChMkuiGFkKH5SrLs451zd3HDs915cbdby_OF6n69FcY5s8fp2SGpxAlu-XxVV2pe5czzHDOPNW7W4esPY1-nXhaSweaETBrNbAHvvVV-qMK9gJ-AxBdlDqJCRLzJuapLbsDyywLma63o-KkikZXbBdkZXN7pPoPvU6kxe-fw4ycTdRDS5Sk3_FKOtjg== https://www.euro.who.int/en/health-topics/communicable-diseases/influenza/seasonal-influenza/burden-of-influenza [11] Trigueiro-Loruro JM, et al. Virol. 2019;535:297-307. [12] Mifsud, EJ, et al. Antiviral Res. 2019;169:104545. [13] Hayden FG, & Pavia AT. Antiviral management of seasonal and pandemic influenza. J Infect Dis. 2006;194:S119--126. [14] Uyeki TM, et al. Clinical practice guidelines by the Infectious Diseases Society of America: 2018 update on diagnosis, treatment, chemoprophylaxis, and institutional outbreak management of seasonal influenza. Clin Infect Dis. 2019; doi:10.1093/cid/ciy866. [15] Wallick C, et al. Presented at: IDWeek; 2018 October 3-7; San Francisco. Abstract #2347. [16] Centers for Disease Control and Prevention. What You Should Know About Flu Antiviral Drugs. [Internet; cited 2020 November]. Available from: https://www.globenewswire.com/Tracker?data=8bMQ-w4R4B0FCrxi1j0taSaIOH4mijXNVTdXaopdrk540AwjGxj0OVASa341SESmXFp9BSfe7LLUbI4P97Y9yZl2a6Tad97RvPnHPgBLrxE0-ie_BuVbTsw_53E-h-HQXHONOQPBT1RDLl_nhQnOX0Laj3X2UYWvcV4RdF1_7ZQ= https://www.cdc.gov/flu/treatment/whatyoushould.htm [17] Noshi T, et al. In vitro Characterization of Baloxavir Acid, a First-in-Class Cap-dependent Endonuclease Inhibitor of the Influenza Virus Polymerase PA Subunit. Antiviral Research. 2018; 160:109-117. [18] Taniguchi K, et al. Inhibition of avian-origin influenza A (H7N9) virus by the novel cap-dependent endonuclease inhibitor baloxavir marboxil. Scientific Reports. 2019; 9:3466. [19] Noshi T, et al. S-033447/S-033188, a Novel Small Molecule Inhibitor of Cap-dependent Endonuclease of Influenza A and B Virus. [20] In Vitro Antiviral Activity against Laboratory Strains of Influenza A and B Virus in Madin-Darby Canine Kidney Cells. Poster presentation at OPTIONS IX, August 2016. Roche Group Media Relations Phone: +41 61 688 8888 / e-mail: https://www.globenewswire.com/Tracker?data=FYgrBMAt4uHXizJ52cr8TDfPcv9-nlIsVdP_6516wPHFR0k20pLqrkPJugerLB229eyxFA9uRW3uwqWcMHTmWlUqzWhj6Df1CE57vj1cpN1Ps_ZPf955HXIKY_rtC2zO media.relations@roche.com Dr. Nicolas Dunant Patrick Barth Phone: +41 61 687 05 17 Phone: +41 61 688 44 86 Dr. Daniel Grotzky Karsten Kleine Phone: +41 61 688 31 10 Phone: +41 61 682 28 31 Nina Mählitz Nathalie Meetz Phone: +41 79 327 54 74 Phone: +41 61 687 43 05 Dr. Barbara von Schnurbein Phone: +41 61 687 89 67 Roche Investor Relations Dr. Karl Mahler Jon Kaspar Bayard Phone: +41 61 68-78503 Phone: +41 61 68-83894 e-mail: mailto:karl.mahler@roche.com e-mail: mailto:jon_kaspar.bayard@roche.com karl.mahler@roche.com jon_kaspar.bayard@roche.com -------------------------------------------- ------------------------------------------- Dr. Sabine Borngräber Dr. Bruno Eschli Phone: +41 61 68-88027 Phone: +41 61 68-75284 e-mail: mailto:sabine.borngraeber@roche.com e-mail: mailto:bruno.eschli@roche.com sabine.borngraeber@roche.com bruno.eschli@roche.com -------------------------------------------- ------------------------------------------- Dr. Birgit Masjost Dr. Gerard Tobin Phone: +41 61 68-84814 Phone: +41 61 68-72942 e-mail: mailto:birgit.masjost@roche.com e-mail: mailto:gerard.tobin@roche.com birgit.masjost@roche.com gerard.tobin@roche.com -------------------------------------------- ------------------------------------------- Investor Relations North America Loren Kalm Dr. Lisa Tuomi Phone: +1 650 225 3217 Phone: +1 650 467 8737 e-mail: mailto:kalm.loren@gene.com e-mail: mailto:tuomi.lisa@gene.com kalm.loren@gene.com tuomi.lisa@gene.com -------------------------------------------- ------------------------------------------- Attachment -- 11012021_Xofluza_EC approval_en https://ml-eu.globenewswire.com/Resource/Download/20d2adda-ac6d-4578-8918-10c0e54ba247
(END) Dow Jones Newswires
January 11, 2021 01:00 ET (06:00 GMT)